{
    "clinical_study": {
        "@rank": "148174", 
        "arm_group": [
            {
                "arm_group_label": "Moderate altitude sojourn", 
                "arm_group_type": "Experimental", 
                "description": "Sojourn at moderate altitude (2048 m)"
            }, 
            {
                "arm_group_label": "Low altitude sojourn", 
                "arm_group_type": "Experimental", 
                "description": "Sojourn at low altitude (490 m, baseline)"
            }, 
            {
                "arm_group_label": "Oxygen", 
                "arm_group_type": "Active Comparator", 
                "description": "Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m"
            }, 
            {
                "arm_group_label": "Sham oxygen (room air)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the effect of travelling to moderate altitude\n      and of nocturnal oxygen therapy during a stay at moderate altitude on exercise performance\n      of patients with pulmonary hypertension or with interstitial lung disease."
        }, 
        "brief_title": "Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Exercise Performance", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Precapillary Pulmonary Hypertension", 
            "Interstitial Lung Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Hypertension, Pulmonary", 
                "Lung Diseases", 
                "Lung Diseases, Interstitial"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with pulmonary hypertension or with interstitial lung disease living below 800 m\n      will be invited to participate in a randomized, cross-over field trial evaluating the\n      hypotheses that: a), exercise capacity during a 2 day sojourn at moderate altitude is\n      reduced in comparison to low altitude; b), exercise capacity during a 2 day sojourn at\n      moderate altitude is improved by nocturnal oxygen therapy compared to room air (sham oxygen)\n      administered during nights at altitude. Outcomes will be assessed at low altitude (Zurich,\n      490 m, baseline), and during 2 study periods of 2 days each spent at moderate altitude (St.\n      Moritz Salastrains, 2048 m), separated by a wash-out period of at least 2 weeks spent at low\n      altitude (<800 m). The order of stays at the different altitudes and of the treatments will\n      be randomized."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Precapillary pulmonary hypertension, or interstitial lung disease.\n\n          -  New York Heart Association class 2-3.\n\n          -  Residence at low altitude (<800m).\n\n        Exclusion Criteria:\n\n          -  Unstable or exacerbated condition\n\n          -  Very severe pulmonary hypertension or interstitial lung disease, New York Heart\n             Association class 4\n\n          -  Requirement for oxygen therapy at low altitude residence\n\n          -  Hypoventilation\n\n          -  More than mild or unstable cardiovascular disease\n\n          -  Use of drugs that affect respiratory center drive\n\n          -  Internal, neurologic or psychiatric disease that interfere with protocol compliance\n             including current heavy smoking (>20 cigarettes per day), inability to perform 6 min\n             walk test.\n\n          -  Previous intolerance to moderate altitude (<2600m).\n\n          -  Exposure to altitudes >1500m for >2 days within the last 4 weeks before the study.\n\n          -  Pregnant or nursing patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143687", 
            "org_study_id": "ID  2013-0088V2A3C"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Moderate altitude sojourn", 
                    "Low altitude sojourn", 
                    "Oxygen", 
                    "Sham oxygen (room air)"
                ], 
                "description": "Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days", 
                "intervention_name": "Moderate altitude sojourn", 
                "intervention_type": "Behavioral", 
                "other_name": "Moderate altitude sojourn at 2048 m for 2 days"
            }, 
            {
                "arm_group_label": [
                    "Moderate altitude sojourn", 
                    "Low altitude sojourn", 
                    "Oxygen", 
                    "Sham oxygen (room air)"
                ], 
                "description": "Low altitude baseline evaluations will be performed during a stay at Zurich (490)", 
                "intervention_name": "Low altitude sojourn", 
                "intervention_type": "Behavioral", 
                "other_name": "Low altitude sojourn at 490 m (Zurich) for 1.5 days"
            }, 
            {
                "arm_group_label": [
                    "Moderate altitude sojourn", 
                    "Low altitude sojourn", 
                    "Oxygen", 
                    "Sham oxygen (room air)"
                ], 
                "description": "Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m", 
                "intervention_name": "Oxygen", 
                "intervention_type": "Drug", 
                "other_name": "Nocturnal nasal oxygen administration during stay at 2048 m"
            }, 
            {
                "arm_group_label": [
                    "Moderate altitude sojourn", 
                    "Low altitude sojourn", 
                    "Oxygen", 
                    "Sham oxygen (room air)"
                ], 
                "description": "Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m", 
                "intervention_name": "Sham oxygen (room air)", 
                "intervention_type": "Drug", 
                "other_name": "Nocturnal nasal room air administration"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sevoflurane"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pulmonary hypertension", 
            "Interstitial lung disease", 
            "Pulmonary fibrosis"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "contact": {
                "email": "konrad.bloch@usz.ch", 
                "last_name": "Konrad E Bloch, MD", 
                "phone": "+41 44 255 3828"
            }, 
            "contact_backup": {
                "email": "tsogyal.latshang@usz.ch", 
                "last_name": "Tsogyal D Latshang, MD", 
                "phone": "+41 44 255 3828"
            }, 
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland", 
                    "zip": "CH-8091"
                }, 
                "name": "University Hospital Zurich, Pulmonary Division"
            }, 
            "investigator": {
                "last_name": "Konrad E Bloch, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "4", 
        "official_title": "Patients With Pulmonary Hypertension or Interstitial Lung Disease Travelling to Altitude - Effect of Nocturnal Oxygen Therapy on Exercise Performance", 
        "overall_contact": {
            "email": "konrad.bloch@usz.ch", 
            "last_name": "Konrad E Bloch, MD", 
            "phone": "+41 44 255 3828"
        }, 
        "overall_contact_backup": {
            "email": "tsogyal.latshang@usz.ch", 
            "last_name": "Tsogyal D Latshang, MD", 
            "phone": "+41 44 255 3828"
        }, 
        "overall_official": {
            "affiliation": "University Hospital, Z\u00fcrich", 
            "last_name": "Konrad E Bloch, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Ethikkommission", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Difference in the distance walked in 6 min between measurements at 2048 m (altitude) and 490 m (baseline); and between the oxygen and sham oxygen treatment periods at 2028 m.", 
            "measure": "6 min walk distance", 
            "safety_issue": "No", 
            "time_frame": "Day 2 at 2048 m"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143687"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Difference in the distance walked in 6 min between measurements at 2048 m (altitude) and 490 m (baseline); and between the oxygen and sham oxygen treatment periods at 2028 m.", 
                "measure": "6 min walk distance", 
                "safety_issue": "No", 
                "time_frame": "day 3 at 2048 m"
            }, 
            {
                "description": "Change in arterial oxygen partial pressure, carbon dioxide partial pressure, and pH between measurements at 2048 m (altitude) and 490 m (baseline); and between the oxygen and sham oxygen treatment periods at 2028 m.", 
                "measure": "Arterial blood gas analysis", 
                "safety_issue": "No", 
                "time_frame": "Day 2 at 2048 m"
            }, 
            {
                "description": "Difference in spirometry between measurements at 2048 m (altitude) and 490 m (baseline); and between the oxygen and sham oxygen treatment periods at 2028 m.", 
                "measure": "Spirometry", 
                "safety_issue": "No", 
                "time_frame": "Day 2 at 2048 m"
            }, 
            {
                "description": "Difference in the perceived exertion rated with the BORG CR10 scale at the end of the 6 min walk between measurements at 2048 m (altitude) and 490 m (baseline); and between the oxygen and sham oxygen treatment periods at 2028 m.", 
                "measure": "Perceived exertion", 
                "safety_issue": "No", 
                "time_frame": "Day 2 at 2048 m"
            }, 
            {
                "description": "Difference in the perceived exertion rated with the BORG CR10 scale at the end of the 6 min walk between measurements at 2048 m (altitude) and 490 m (baseline); and between the oxygen and sham oxygen treatment periods at 2028 m.", 
                "measure": "Perceived exertion", 
                "safety_issue": "No", 
                "time_frame": "Day 3 at 2048 m"
            }, 
            {
                "description": "Number of participants in whom arterial oxygen saturation measured by pulse oximetry is less than 75% for more than 30 min during the sojourn at 2048 m (altitude) and 490 m (baseline); and during the oxygen and sham oxygen treatment periods at 2028 m.", 
                "measure": "Severe hypoxemia", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to 3 at 2048 m"
            }
        ], 
        "source": "University of Zurich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}